This two-part continuing educational program has been designed to enhance nurses' foundational knowledge of — and expand their competencies in — managing patients with Pulmonary Arterial Hypertension (PAH).
Pulmonary Arterial Hypertension (PAH) is a hemodynamic and pathophysiological state associated with several clinical conditions that can lead to progressive right ventricular failure and death[1].
Although complex and difficult to treat, new knowledge about its pathophysiology has led to developments in diagnostic and multiple treatment options that can reduce symptoms and prolong life.
These developments are especially significant since the typical PAH patient is a relatively young woman (average age 53 years) in the prime of life, who experiences severe physical and emotional limitations to daily life as a consequence of breathlessness, fatigue, comorbidities, and treatment that can be invasive and painful.
About PAHTap to read more...
Pulmonary Arterial Hypertension (PAH) is a hemodynamic and pathophysiological state associated with several clinical conditions that can lead to progressive right ventricular failure and death[1].
Although complex and difficult to treat, new knowledge about its pathophysiology has led to developments in diagnostic and multiple treatment options that can reduce symptoms and prolong life.
These developments are especially significant since the typical PAH patient is a relatively young woman (average age 53 years) in the prime of life, who experiences severe physical and emotional limitations to daily life as a consequence of breathlessness, fatigue, comorbidities, and treatment that can be invasive and painful.
Learning objectivesWhat you'll achieve...
At the end of this Continuing Education activity, participants should be able to:
- Identify patients at risk for pulmonary arterial hypertension
- List the symptoms of pulmonary arterial hypertension
- Describe the therapeutic regimens for the management of pulmonary arterial hypertension and their associated toxicities
- Develop strategies for self-care and medication adherence in patients with pulmonary arterial hypertension
DisclosuresFor complete transparency...
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs developed by San Lucas Medical and MDSNe must demonstrate balance, independence, objectivity, and scientific rigor.
All faculty, authors, editors, and planning committee members participating in activities developed by San Lucas Medical and MDSNe are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
Financial Disclosure
Wendy Gin-Sing, APRN, has received honoraria from Bayer, Actelion, GlaxoSmithKline, United Therapeutics, and has received support for conference registration and travel from Actelion, GlaxoSmithKline, United Therapeutics, and Eli Lilly.
Martha Wagenaar, APRN, has nothing to disclose.
Ellen Vandevelde, APRN, is a member of the Advisory Board of United Therapeutics, for which she received honoraria.
San Lucas Medical and MDSNe staff who contributed to editorial management and review of this activity have nothing to disclose.
Unlabeled Use Disclosure
Faculty of this continuing educational activity may include discussions of products or devices that are not currently labeled for use by the European Medicines Agency. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the European Medicines Agency) of products or devices.
San Lucas Medical, MDSNe, and United Therapeutics do not endorse the use of any product outside of the European Medicines Agency labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patients.
